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OBJECTIVES This investigation was designed to determine the relationship between National Cholesterol
Education Program (NCEP) ATP-II lipid guidelines and subclinical atherosclerosis, defined
by electron beam tomography (EBT) calcified coronary plaque, in asymptomatic women.
BACKGROUND NCEP guidelines are used to identify women at increased risk for coronary artery disease
(CAD) on the basis of low density lipoprotein cholesterol (LDLC) and high density
lipoprotein cholesterol (HDLC) values. The relationship of the guidelines to subclinical
atherosclerosis is unknown.
METHODS A total of 304 asymptomatic women underwent lipid and EBT evaluation and were classified
as: 1) NCEP higher risk, with LDLC $130 mg/dl and/or HDLC ,35 mg/dl, or lower risk
with LDLC ,130 mg/dl and HDLC $35 mg/dl; and 2) EBT1 if any calcified plaque was
noted or EBT2 if there was no calcified plaque.
RESULTS Forty-two percent of patients were EBT1, with a mean score of 227 and percentile of 73%;
58% were EBT2. Women who were EBT1 had significantly higher total cholesterol,
LDLC and triglycerides than EBT2 women, but only with ages #55 years; women .55
years demonstrated no differences. NCEP higher risk women made up 53.5% of the EBT1
and 37.7% of the EBT2 groups; NCEP lower risk women accounted for 46.5% of the EBT1
and 62.3% of the EBT2 groups. Assuming a higher risk in subjects with EBT2defined
subclinical CAD than in those without, only 58.6% of the total group would be correctly
identified by NCEP guidelines as either higher or lower risk, with correct identification of
65.5% of the younger and 52.2% of the older women. There was no correlation between either
calcium percentile or score and any lipid measurement.
CONCLUSIONS This study demonstrates the shortcomings of employing NCEP guidelines to identify
asymptomatic women with subclinical CAD, particularly women .55 years, and suggests
increased utilization of EBT for primary prevention in the female population. (J Am Coll
Cardiol 2001;37:1506–11) © 2001 by the American College of Cardiology
Coronary artery disease (CAD) is the leading cause of death
of American women (1). Yet, it receives far less attention
than breast cancer, for which routine screening by mam-
mography is routinely performed. American Heart Associ-
ation statistics reveal that breast cancer killed 41,943 women
in 1997, compared to 502,938 for CAD (1). The delayed
development of CAD in women may lead to a false sense of
security regarding the number of pre and post menopausal
women who have subclinical CAD and may benefit from
primary prevention. Once women manifest CAD, they fare
worse than men; 42% of women who have heart attacks die
within a year compared to 24% of men (1).
See page 1512
The foundation of CAD primary prevention is the
identification and modification of the classic CAD risk
factors and treatment of lipid disorders according to the
National Cholesterol Education Program (NCEP) ATP-II
guidelines (2). Dietary intervention is recommended for low
density lipoprotein cholesterol (LDLC) $130 mg/dl and
$2 risk factors and drug therapy for LDLC $160 mg/dl.
High density lipoprotein cholesterol (HDLC) ,35 mg/dl is
also considered to pose increased risk.
Electron beam tomography (EBT) evaluation of calcified
coronary plaque burden has been validated by an increasing
body of evidence supporting its correlation with total plaque
volume (3–13), obstructive CAD (6–13) and clinical prog-
nosis (14–18). Unlike mammography, EBT has not yet
been recommended for screening the general population
(19), but has been suggested as a tool to identify asymp-
tomatic individuals who may benefit from specific practice
guidelines (20).
This investigation was designed to determine whether the
NCEP guidelines for defining higher and lower risk accu-
rately identify subclinical atherosclerosis in both younger
and older women, as defined by EBT evidence of calcified
plaque. Further, the relationship between the levels of
conventional blood lipid measurements and the absolute
and age-corrected amount of calcified plaque was evaluated.
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METHODS
Subjects. Three hundred nineteen consecutive asymptom-
atic women undergoing EBT at the Arizona Heart Insti-
tute, self-referred out of personal concern for CAD risk,
filled out a medical history questionnaire and were evalu-
ated. Hypertension was defined by current or recommended
use of antihypertensive medications for blood pressure
control. Smoking was defined as current tobacco usage and
diabetes by current or recommended use of diet or medica-
tion to reduce blood sugar. Family history of CAD was
defined as CAD in first-degree male relatives #55 years of
age or female relatives #65 years. Body mass index was
calculated as weight (kg)/height (m)2.
In order to explore the potential effects of younger and
older age, the group was divided into women # 55 and .55
years of age. The age of 55 years was selected because
women presenting to emergency departments with chest
pain are more likely to be misdiagnosed if they are #55
years of age, and, women .55 years of age are likely to be
postmenopausal (21). Fifteen women were on lipid-
lowering drug therapy (statins, fibrates or niacin) and were
excluded, resulting in a final population of 304 women.
Imaging. Electron beam tomography was performed using
an Imatron C-150 (San Francisco, California) scanner.
Forty contiguous 3-mm slices were acquired during a single
breathhold beginning at the carina with a 350 mm scan
field, 100 ms/slice scan time and triggered at 80% of the
R-R interval. Two contiguous pixels with attenuation coef-
ficient .130 Hounsfield units were the minimum require-
ment for a calcium deposit. The coronary artery score,
corresponding to the amount of plaque, was calculated with
the Agatston (22) method by a technologist and reviewed by
a physician blinded to all clinical data. The calcium percen-
tile, an age- and gender-corrected index of plaque burden
prematurity (17,23) shown to be powerfully related to
prognosis (17), was derived from the University of Illinois
database of 19,200 asymptomatic men and women by
assigning a percentile comparing an individual’s calcium
score to database subjects of identical age and gender. For
example, a 60-year-old woman in the 75th percentile has
more calcium than 74% and less than 25% of 60-year-old
women in the database.
Subjects with calcium scores .0 were classified as
EBT1; those without detectable coronary calcium were
classified as EBT2.
Laboratory. Fasting total cholesterol (TC) and triglycer-
ides (TG) were determined using enzymatic methods on
samples drawn on the same day as the EBT. High density
lipoprotein cholesterol was measured after precipitation of
apo B containing particles with phosphotungstate. Low
density lipoprotein cholesterol was calculated using the
Friedewald equation. The Framingham risk score was used
to determine each subject’s computed risk (24).
Subjects were classified as NCEP higher or lower risk as
follows: NCEP higher risk 5 LDLC $130 and/or HDLC
,35 mg/dl; NCEP lower risk 5 LDLC ,130 and HDLC
$35 mg/dl.
Statistical analysis. Tests of significance between groups
were determined by using Student t test with the level of
significance set at p , 0.05 (two-tailed). Chi-square analysis
was used to test for differences between dichotomous
variable groups. The STATVIEW (v.4.1) (Berkeley, Cali-
fornia) statistical package was used for all analyses.
RESULTS
Demographics, mean (6 SD) plasma lipid values and mean
(6 SD) EBT results of the total population are shown in
Table 1. A family history of premature CAD was common
and was found in 50.7%. A history of hypertension was
present in 17.8%, smoking in 7.2% and diabetes in 2.6%.
The mean lipid values were not abnormal and were well
within NCEP guidelines. The mean EBT calcium score of
96.1 was in the moderate range and the average subject was
in the 31st percentile. NCEP higher risk was noted in
47.7% of the women and lower risk in 52.3%.
EBT1 versus EBT2. EBT1 and EBT2 women are
compared in Table 1; 42% were EBT1 and 58% were
EBT2. The EBT1 group was older (p 5 0.0001) and
more likely to have a history of hypertension (p 5 0.005)
compared with the EBT2 group. There were no significant
differences between EBT1 and EBT2 groups for body
mass index, diabetes, smoking history or family history of
CAD. Total cholesterol (p 5 0.0004), LDLC (p5 0.005)
and TG (p 5 0.02) were significantly higher in the EBT1
compared with the EBT2 group. In the EBT1 group,
53.5% were classified as NCEP higher risk and 46.5% as
NCEP lower risk. In the EBT2 group, 62.3% were
classified as NCEP lower risk and 37.7% as NCEP higher
risk. Assuming a higher risk in subjects with EBT-defined
subclinical CAD than in those without, correct identifica-
tion by NCEP guidelines of either higher or lower risk was
noted in 58.6% of the women.
The Framingham risk score was significantly higher in
the EBT1 versus EBT2 group in the total cohort of
women, but was heavily influenced by the age difference.
With age removed from the Framingham risk calculation,
there was no significant difference between groups. The
mean calcium score in the EBT1 group was 227, in the
moderately severe range. The mean calcium percentile was
Abbreviations and Acronyms
CAD 5 coronary artery disease
EBT 5 electron beam tomography
HDLC 5 high density lipoprotein cholesterol
LDLC 5 low density lipoprotein cholesterol
NCEP 5 National Cholesterol Education Program
SD 5 standard deviation
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73%, and 90% of the subjects had scores that were in the
53rd percentile or higher (mean 21 SD).
The analysis of women #55 years of age is presented in
Table 2. The total cholesterol (p 5 0.04) and LDLC (p 5
0.02) were significantly higher in the EBT1 group com-
pared with the EBT2 group. There were no significant
differences in HDLC or age. The percentage of individuals
classified as NCEP higher risk was significantly higher and
the percentage of subjects classified as NCEP lower risk was
significantly lower in the EBT1 compared with the EBT2
group (p 5 0.01), but 42.4% of the lower risk group were
EBT1. Framingham risk scores were significantly higher in
the EBT1 group (p 5 0.004), primarily attributed to
differences in LDLC. A history of hypertension was noted
more frequently in the EBT1 compared with the EBT2
group (p 5 0.006). Other potential contributors to CAD
risk, including a family history of CAD, diabetes mellitus
and cigarette smoking, were not significantly different.
Correct identification by NCEP guidelines of either higher
or lower risk was observed in 65.5% of the younger group.
The analysis of women .55 years of age is presented in
Table 3. The EBT1 group was significantly older than the
EBT2 group (p 5 0.0004), but there were no significant
differences in any lipid measurements or other potential
contributors to CAD risk between the groups, and the
Framingham risk scores were similar. NCEP higher and
lower risk lipid profiles were equally distributed between the
EBT1 and EBT2 groups and were ;50% in each cate-
gory. Correct identification by NCEP guidelines of either
higher or lower risk was noted in 52.2% of the .55 years of
age cohort.
In the entire group of women, age was significantly
Table 1. Demographics, Plasma Lipid Values and EBT results in the Total Group and in
EBT1 vs. EBT2 Women
Total
Group EBT1 EBT2 p Value
n 304 129 175
Age (yrs) 57.3 6 11.3 62.7 6 10.8 53.0 6 9.9 0.0001
Body mass index 30.3 6 16.4 28.9 6 7.8 31.4 6 20.9 0.25
Family history of CAD 50.7% 55.0% 47.4% 0.19
History of hypertension 17.8% 24.8% 12.6% 0.005
Smoker 7.2% 4.7% 9.1% 0.14
History of diabetes 2.6% 3.9% 1.7% 0.25
TC (mg/dl) 218 6 43 228 6 42 211 6 43 0.0004
LDLC (mg/dl) 126 6 40 133 6 42 120 6 38 0.005
HDLC (mg/dl) 66.6 6 19 66.4 6 18.2 66.9 6 19.6 0.82
TC/HDLC 3.5 6 1.2 3.7 6 1.1 3.4 6 1.2 0.06
TG (mg/dl) 125 6 80 138 6 77 116 6 81 0.02
EBT calcium score 96.1 6 311 227 6 446 0 6 0
EBT calcium percentile 31.2 6 38.6 73.4 6 20.2 0 6 0
NCEP higher risk 47.7% 53.5% 37.7%
0.006
NCEP lower risk 52.3% 46.5% 62.3%
Framingham risk score 7.3 6 3.8 5.0 6 3.4 0.0001
CAD 5 coronary artery disease; EBT 5 electron beam tomography; HDLC 5 high density lipoprotein cholesterol; LDLC 5
low density lipoprotein cholesterol; NCEP 5 National Cholesterol Education Program; TC 5 total cholesterol; TG 5
triglycerides.
Table 2. Comparison of EBT1 vs. EBT2 Women #55 Years
of Age
EBT1 EBT2 p Value
n 33 112
Age (yrs) 49.1 6 6.0 47.3 6 6.1 0.13
Body mass index 31.0 6 8.3 30.2 6 7.9 0.65
TC (mg/dl) 226 6 43 207 6 48 0.04
LDLC (mg/dl) 138 6 43 118 6 42 0.02
HDLC (mg/dl) 62.0 6 15.3 66.0 6 21.1 0.31
TC/HDLC 3.9 6 1.1 3.4 6 1.4 0.10
TG (mg/dl) 131 6 63 113 6 80 0.24
NCEP higher risk 57.6% 32.1%
0.01
NCEP lower risk 42.4% 67.9%
Framingham risk score 5.5 6 4.1 3.8 6 2.6 0.004
Calcium score 75.5 6 106.1 0
Calcium percentile 83.8 6 13.9 0
EBT 5 electron beam tomography; HDLC 5 high density lipoprotein cholesterol;
LDLC 5 low density lipoprotein cholesterol; NCEP 5 National Cholesterol
Education Program; TC 5 total cholesterol; TG 5 triglycerides.
Table 3. Comparison of EBT1 vs. EBT2 Women .55 Years
of Age
EBT1 EBT2 p Value
n 96 63
Age (yrs) 67.4 6 7.6 63.1 6 6.5 0.0004
Body mass index 28.2 6 7.6 33.4 6 33.1 0.18
TC (mg/dl) 229 6 41 218 6 32 0.06
LDLC (mg/dl) 132 6 42 125 6 29 0.28
HDLC (mg/dl) 67.9 6 19.0 68.4 6 16.7 0.86
TC/HDLC 3.6 6 1.1 3.4 6 0.9 0.16
TG (mg/dl) 140 6 81 120 6 81 0.13
NCEP higher risk 52.1% 47.6%
0.58
NCEP lower risk 47.9% 52.4%
Framingham risk score 7.9 6 3.6 7.3 6 3.3 0.27
Calcium score 279 6 503 0
Calcium percentile 69.8 6 20.8 0
EBT 5 electron beam tomography; HDLC 5 high density lipoprotein cholesterol;
LDLC 5 low density lipoprotein cholesterol; NCEP 5 National Cholesterol
Education Program; TC 5 total cholesterol; TG 5 triglycerides.
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related to coronary calcium score (r 5 0.35, p , 0.0001) and
the calcium scores were higher in women .55 compared
with #55 years of age (279 6 503 vs. 75.5 6 106.1, p ,
0.02). Further analysis revealed that the relationship of age
to calcium score was significant in the .55 years of age
group (r 5 0.33, p , 0.0001) but not in the #55 years of
age group (r 5 0.07, p 5 0.39). The calcium percentiles
were significantly higher in the younger compared with the
older women (83.8 6 13.9 vs. 69.8 6 20.8, p , 0.0005).
Calcium percentile, calcium score and lipid levels. In the
EBT1 group there were no significant correlations between
calcium percentile and LDLC (r 5 0.06, p 5 0.49) (Fig. 1),
HDLC (r 5 0.03, p 5 0.73) (Fig. 2), TC/HDLC (r 5
0.001, p 5 0.99) or TG (r 5 0.04, p 5 0.70). A similar
absence of significant correlation was noted between cal-
cium score and LDLC (r 5 0.10, p 5 0.29), HDLC (r 5
0.17, p 5 0.06), TC/HDLC (r 5 0.001, p 5 0.99) and TG
(r 5 0.11, p 5 0.23).
DISCUSSION
This investigation, for the first time, defines the relation-
ship between NCEP higher and lower risk lipid guidelines
and subclinical atherosclerosis in asymptomatic women as
determined by EBT. It also demonstrates that the amount
and prematurity of calcified plaque are not related to levels
of the conventional lipid parameters.
General population. As expected, EBT1 women were
significantly older than the EBT2 cohort and age ac-
counted for a large portion of the difference in the Framing-
ham risk scores between the groups. When age was elimi-
nated from the Framingham risk calculation there was no
significant difference between groups. Standard cardiovas-
cular risk factors, including the presence of diabetes melli-
tus, smoking, hypertension and family history of CAD did
not explain the difference between EBT1 and EBT2
women. Although total and LDL cholesterol were signifi-
cantly higher in the EBT1 compared with the EBT2
group, the number of women with coronary calcification
who would have been placed into the NCEP lower risk
group (46.5%) is troubling from the clinical standpoint. The
definition of NCEP lower risk used in this analysis em-
ployed an LDLC cut point of 130 mg/dl. If an LDLC cut
point of 160 mg/dl (the value above which NCEP recom-
mends drug therapy) had been used instead, a significantly
greater number of women (75.2%, p 5 0.0001) would have
been classified as lower risk, yet exhibit evidence of CAD as
represented by coronary calcification. Moreover, those
women classified as lower risk had calcium scores and percen-
tiles indistinguishable from those classified as higher risk.
Older versus younger women. Analyses of women #55
and .55 years of age reveal that statistically significant
differences between EBT1 and EBT2 cohorts exist pri-
marily in the younger age group, and are limited to higher
total cholesterol and LDLC in the EBT1 group, accom-
panied by a higher incidence of NCEP higher risk and a
lower incidence of NCEP lower risk subjects. A history of
hypertension was reported in significantly more EBT1
younger than older women. Even in the younger cohort,
however, only 57.6% of the EBT1 group was identified by
NCEP higher risk lipid guidelines. In the older group there
were no significant differences between the EBT1 and
EBT2 groups in any lipid measurement, NCEP higher and
lower risk distribution, Framingham risk scores or demo-
graphic variables. Only 52.1% of the older EBT1 women
were identified by NCEP guidelines. The calcium scores
were lower in the #55 year cohort but the calcium percen-
tiles were significantly higher, suggesting a more aggressive
process in the younger group.
Relevance of EBT. The importance of these findings is
dependent on the relevance of EBT calcified plaque to
CAD. The past decade has seen a proliferation of docu-
mentation, by postmortem studies (3–5), angiography (5–
13) and intravascular ultrasound (25,26), of the direct
proportionality of calcified plaque to total coronary plaque
Figure 1. Correlation of electron beam tomography (EBT) calcium per-
centile and low density lipoprotein cholesterol (LDLC) in EBT1 women.
r 5 0.06, p5 0.49.
Figure 2. Correlation of electron beam tomography (EBT) calcium per-
centile and high density lipoprotein cholesterol (HDLC) in EBT1
women. r 5 0.03, p5 0.73.
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burden and obstructive CAD. This has been accompanied
by reports substantiating the poorer prognosis (14–18) and
likelihood of ischemia (27) associated with both increasing
calcium score and increasing calcium percentile (17), as well
as the superiority of EBT findings to conventional risk
factors (17). The assumption that a population of women
with a mean calcium score of 227 and percentile of 73%
(i.e., the EBT1 group in this study) is at higher risk than a
population of women with 0 scores is supported by all
published studies as well as the recent ACC/AHA Consen-
sus statement on EBT (19): “A negative test may be
consistent with a low risk of a cardiovascular event in the
next 2 to 5 years . . . A high calcium score may be consistent
with moderate to high risk of a cardiovascular event within
the next 2 to 5 years.” Dissemination of the concept that
calcified plaque is not itself a risk factor, but rather reflects
the effect or lack thereof of all risk factors on the endothe-
lium, is crucial to identifying subjects who should be
targeted for primary prevention.
The crucial role played by NCEP guidelines in promot-
ing awareness of the need to identify and treat lipid
disorders is incontrovertible. However, the lack of close
correlation between the conventional lipid parameters that
are incorporated into the NCEP higher and lower risk
guidelines and the presence or absence of subclinical CAD
suggests a possible role for other contributing factors.
Investigation into LDL subclass distribution differences,
Lp(a), homocysteine, infectious and inflammatory etiologies
may provide some of the missing links (28–30).
The striking lack of correlation between any of the
standard lipid measurements and the amount and percentile
of calcified plaque (Figs. 1 and 2 and Results section),
although counterintuitive, is consistent with arteriographic
investigations of CAD patients, unselected for abnormal
lipids, that have revealed no correlation between LDLC and
disease severity (31,32) and further strengthens the necessity
for identifying the agents that promote plaque development
at levels of lipids not conventionally thought to be associated
with CAD. It reinforces the observations from large clinical
trials that report outcome improvements ,40% in response
to LDLC (33,34) and HDLC treatment (35) and the
Framingham observation that 80% of people who develop
CAD have the same total cholesterol as those who do not
develop CAD (36).
Clinical implications. Guidelines, by their nature, extrap-
olate conclusions from large population-based studies to
decision making in individual patients, in whom such
conclusions may or may not be relevant. Application of the
NCEP higher and lower risk lipid guidelines to this population
of asymptomatic women would not identify subclinical
atherosclerosis, and therefore would result in neither dietary
nor drug treatment of 47% of the individuals who have it.
Moreover, those women who would not be treated, those
with lower LDLC and higher HDLC levels, have similar
amounts of total and age-corrected calcified plaque as those
for whom treatment would be recommended. Conversely,
treatment would be recommended for 37.7% of women who
have no EBT evidence for subclinical atherosclerosis.
Of the total population, only 58.6% would be correctly
identified as being either at higher or lower risk by the
NCEP guidelines, using calcified plaque as the reference
point. Women #55 years of age appear to be better served
by the guidelines than those .55 years of age, with correct
identification of 65.5% in the younger group compared with
52.2% in the older cohort. The shortcomings of using
conventional lipid parameters are supported by Kuller et al.
(37), who noted that treatment decisions such as lipid-
lowering therapy based only on LDLC (130 mg/dl) and
HDLC (,60 mg/dl) levels before menopause excluded the
majority of women who had high calcium scores 10 years
later and included many who had minimal risk of high
coronary calcium scores. It appears reasonable, therefore, to
incorporate the results of EBT evaluation into the decision-
making process in individual patients to more appropriately
allocate treatment to women who have already demon-
strated unequivocal evidence for subclinical atherosclerosis.
The underappreciated magnitude of CAD in women, far
exceeding breast cancer, may warrant wider scale implemen-
tation of EBT in the asymptomatic population.
Study limitations. Several factors may affect interpretation
of the results of this investigation. First, this study did not
measure clinical outcomes. However, there are considerable
data supporting the direct relationship of EBT-determined
plaque burden to coronary atherosclerosis (3–13) and doc-
umentation of the relationship between increasing plaque
burden and increased CAD event risk (14–18). Second,
there may be women who are at risk on the basis of
exclusively soft, noncalcified plaque who are EBT2. How-
ever, these patients represent a small fraction of those who
experience coronary events (17,26). Third, the bias implicit
in the self-referral nature of a population concerned about
CAD risk may result in conclusions that are not applicable
to the population as a whole. However, they are valid for
this population, reflect the concerns of women oriented
towards primary prevention and are free from any selection
criteria biases, particularly related to hypercholesterolemia.
Fourth, questionnaire-based demographics may not be en-
tirely accurate. However, EBT1 and EBT2 groups would
be equally affected.
Conclusions. This study demonstrates the potential short-
comings of using NCEP guidelines to identify women with
subclinical atherosclerosis, as defined by EBT, who should
be targeted for aggressive primary prevention. Postmeno-
pausal women at risk appear to be particularly difficult to
identify by conventional risk-factor analysis. Use of EBT
may have a significant impact in the treatment of the
leading cause of death in the female population.
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